HCA Healthcare, Inc. $HCA Shares Sold by CENTRAL TRUST Co

CENTRAL TRUST Co lowered its holdings in HCA Healthcare, Inc. (NYSE:HCA) by 14.0% in the second quarter, according to its most recent disclosure with the SEC. The institutional investor owned 778 shares of the company’s stock after selling 127 shares during the period. CENTRAL TRUST Co’s holdings in HCA Healthcare were worth $298,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. Nuveen LLC acquired a new position in HCA Healthcare during the 1st quarter worth $569,217,000. Pacer Advisors Inc. grew its position in shares of HCA Healthcare by 6,237.9% during the first quarter. Pacer Advisors Inc. now owns 1,350,933 shares of the company’s stock worth $466,815,000 after buying an additional 1,329,618 shares in the last quarter. Price T Rowe Associates Inc. MD raised its holdings in HCA Healthcare by 83.4% in the first quarter. Price T Rowe Associates Inc. MD now owns 2,399,372 shares of the company’s stock valued at $829,104,000 after acquiring an additional 1,091,416 shares in the last quarter. Goldman Sachs Group Inc. increased its position in shares of HCA Healthcare by 49.1% in the 1st quarter. Goldman Sachs Group Inc. now owns 1,781,459 shares of the company’s stock valued at $615,583,000 after purchasing an additional 587,036 shares during the last quarter. Finally, Abdiel Capital Advisors LP purchased a new stake in shares of HCA Healthcare during the 1st quarter worth $164,835,000. Institutional investors and hedge funds own 62.73% of the company’s stock.

Insider Buying and Selling

In other news, EVP Michael S. Cuffe sold 3,836 shares of the stock in a transaction dated Monday, September 8th. The shares were sold at an average price of $418.84, for a total value of $1,606,670.24. Following the completion of the transaction, the executive vice president owned 31,503 shares in the company, valued at $13,194,716.52. This trade represents a 10.85% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Michael R. Mcalevey sold 3,892 shares of the company’s stock in a transaction dated Wednesday, November 5th. The stock was sold at an average price of $473.79, for a total transaction of $1,843,990.68. Following the transaction, the executive vice president owned 3,487 shares in the company, valued at $1,652,105.73. The trade was a 52.74% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Corporate insiders own 1.30% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on the company. Wells Fargo & Company upped their price objective on HCA Healthcare from $412.00 to $431.00 and gave the stock an “equal weight” rating in a research report on Thursday. The Goldman Sachs Group increased their price target on shares of HCA Healthcare from $470.00 to $520.00 and gave the company a “buy” rating in a research note on Monday, October 27th. Cowen reaffirmed a “buy” rating on shares of HCA Healthcare in a research report on Monday, October 27th. Weiss Ratings restated a “buy (b-)” rating on shares of HCA Healthcare in a research note on Wednesday, October 8th. Finally, Morgan Stanley set a $425.00 target price on HCA Healthcare in a report on Monday, October 27th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and ten have given a Hold rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $474.53.

HCA Healthcare Stock Performance

Shares of NYSE:HCA opened at $473.42 on Friday. The company has a 50-day simple moving average of $432.52 and a 200-day simple moving average of $395.09. The stock has a market capitalization of $108.03 billion, a price-to-earnings ratio of 18.30, a PEG ratio of 1.38 and a beta of 1.41. HCA Healthcare, Inc. has a one year low of $289.98 and a one year high of $479.43.

HCA Healthcare (NYSE:HCA) last announced its earnings results on Friday, October 24th. The company reported $6.96 earnings per share for the quarter, beating the consensus estimate of $5.64 by $1.32. The company had revenue of $19.16 billion for the quarter, compared to the consensus estimate of $18.55 billion. HCA Healthcare had a negative return on equity of 792.25% and a net margin of 8.53%.The company’s revenue was up 9.6% on a year-over-year basis. During the same period last year, the business posted $4.90 EPS. HCA Healthcare has set its FY 2025 guidance at 27.000-28.000 EPS. As a group, research analysts forecast that HCA Healthcare, Inc. will post 24.98 EPS for the current fiscal year.

HCA Healthcare Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, December 29th. Investors of record on Monday, December 15th will be given a $0.72 dividend. The ex-dividend date is Monday, December 15th. This represents a $2.88 dividend on an annualized basis and a yield of 0.6%. HCA Healthcare’s dividend payout ratio (DPR) is presently 11.13%.

About HCA Healthcare

HCA Healthcare, Inc, through its subsidiaries, owns and operates hospitals and related healthcare entities in the United States. It operates general and acute care hospitals that offers medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy.